Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. That said, here is one value stock trading at a big discount to its intrinsic value and two with little support.

Two value stocks to sell:

Enovis (ENOV)

Forward P/E Ratio: 5.9x

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE: ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Do We Think ENOV Will Underperform?

1. Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last five years
2. Earnings per share fell by 9.5% annually over the last five years while its revenue was flat, showing each sale was less profitable
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $21.60 per share, Enovis trades at 5.9x forward P/E. Check out our free in-depth research report to learn more about why ENOV doesn’t pass our bar.

Pediatrix Medical Group (MD)

Forward P/E Ratio: 11.9x

With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE: MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states.

Why Do We Think Twice About MD?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 1.3% annually over the last two years
2. Subscale operations are evident in its revenue base of $1.95 billion, meaning it has fewer distribution channels than its larger rivals
3. Estimated sales growth of 1.5% for the next 12 months is soft and implies weaker demand

Pediatrix Medical Group is trading at $29.54 per share, or 11.9x forward P/E. Dive into our free research report to see why there are better opportunities than MD.

One value stock to watch:

JBT Marel (JBTM)

Forward P/E Ratio: 12.5x

Tracing back to its invention of the mechanical milk bottle filler in 1884, JBT Marel (NYSE: JBTM) designs, manufactures, and sells equipment used for food processing and aviation.

Why Do We Like JBTM?

1. Impressive 54.6% annual revenue growth over the last two years indicates it’s winning market share this cycle
2. Healthy unit economics are reflected in its 35.4% gross margin and give it more money to invest in marketing and R&D
3. Earnings per share have massively outperformed its peers over the last two years, increasing by 30% annually

JBT Marel’s stock price of $109.66 implies a valuation ratio of 12.5x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks we like even more

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.